Logos Global Management’s Soleno Therapeutics SLNO Stock Holding History

Logos Global Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$8.37M	–	86
2026 Q1	$8.37M	Sell	250,000 -50,000	-17%	-$1.96M	0.42%	50
2025 Q4	$13.9M	Buy	+300,000	New	+$16.4M	0.84%	36
2025 Q2	–	Sell	-250,000	Closed	-$17.9M	–	60
2025 Q1	$17.9M	Sell	250,000 -100,000	-29%	-$4.87M	3.18%	12
2024 Q4	$15.7M	Buy	+350,000	New	+$18.1M	1.84%	21
2023 Q4	–	Sell	-125,000	Closed	-$3.69M	–	68
2023 Q3	$3.69M	Buy	+125,000	New	+$757K	0.49%	44

Logos Global Management's SLNO Position: Q2 2026 in Review

Logos Global Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 250,000 shares — an estimated $8.37M sold.

Logos Global Management first reported a position in SLNO in Q3 2023 and held it in 5 quarters. The position peaked at $17.9M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Logos Global Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Logos Global Management sold 250,000 Soleno Therapeutics shares in Q2 2026, an estimated $8.37M.
Logos Global Management first reported a position in Soleno Therapeutics in Q3 2023 and held it in 5 quarters.
Logos Global Management's Soleno Therapeutics position peaked at $17.9M in Q1 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.